NCT01847274 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 138
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 234
- group Id
- BG003
- value
- 116
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 596
- units
- Participants
- groups
- description
- Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.
- id
- BG000
- title
- gBRCA Niraparib
- description
- Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.
- id
- BG001
- title
- gBRCA Placebo
- description
- Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.
- id
- BG002
- title
- Non-gBRCA Niraparib
- description
- Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression
- id
- BG003
- title
- Non-gBRCA Placebo
- description
- Participants received a single dose of 3x100 mg capsules of niraparib administered orally following a minimum 10-hour overnight fast in Period 1 followed by 300 mg capsules of niraparib administered orally as single dose in fed condition (high-fat meal) in Period 2. There was a washout period of 7 days between treatment periods.
- id
- BG004
- title
- FE Sub-study: Fasted/Fed
- description
- Participants received single dose of 3x100 mg capsules of niraparib administered orally following a high-fat meal in Period 1 followed by 3x100 mg capsules of niraparib administered orally as single dose in fasted condition in Period 2. There was a washout period of 7 days between treatment periods.
- id
- BG005
- title
- FE Sub-study: Fed/Fasted
- description
- Participants received Niraparib 300 mg once daily orally.
- id
- BG006
- title
- QTc Sub-study: Niraparib
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 110
- group Id
- BG001
- value
- 49
- group Id
- BG002
- value
- 130
- group Id
- BG003
- value
- 69
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 16
- group Id
- BG007
- value
- 384
- title
- Between 18 and 64 years
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 104
- group Id
- BG003
- value
- 47
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 212
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 138
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 234
- group Id
- BG003
- value
- 116
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 596
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 20
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 123
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 201
- group Id
- BG003
- value
- 101
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 21
- group Id
- BG007
- value
- 516
- title
- White
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 46
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The baseline analysis population was the intent-to-treat population, defined as all randomized participants with participants analyzed according to the study drug assigned via randomization
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 138
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 234
- group Id
- BG003
- value
- 116
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 596
- units
- Participants
- groups
- description
- Participants with germline breast cancer gene (gBRCA) mutation received oral dose of niraparib 300 milligrams (mg) once daily in 28-day cycles until disease progression.
- id
- BG000
- title
- gBRCA Niraparib
- description
- Participants with germline BRCA mutation received oral dose of placebo matching niraparib once daily in 28-day cycles until disease progression.
- id
- BG001
- title
- gBRCA Placebo
- description
- Participants without germline BRCA mutation received oral dose of niraparib 300 mg once daily orally in 28-day cycles until disease progression.
- id
- BG002
- title
- Non-gBRCA Niraparib
- description
- Participants without germline BRCA mutation received matching placebo once daily orally in 28-day cycles until disease progression
- id
- BG003
- title
- Non-gBRCA Placebo
- description
- Participants received a single dose of 3x100 mg capsules of niraparib administered orally following a minimum 10-hour overnight fast in Period 1 followed by 300 mg capsules of niraparib administered orally as single dose in fed condition (high-fat meal) in Period 2. There was a washout period of 7 days between treatment periods.
- id
- BG004
- title
- FE Sub-study: Fasted/Fed
- description
- Participants received single dose of 3x100 mg capsules of niraparib administered orally following a high-fat meal in Period 1 followed by 3x100 mg capsules of niraparib administered orally as single dose in fasted condition in Period 2. There was a washout period of 7 days between treatment periods.
- id
- BG005
- title
- FE Sub-study: Fed/Fasted
- description
- Participants received Niraparib 300 mg once daily orally.
- id
- BG006
- title
- QTc Sub-study: Niraparib
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 110
- group Id
- BG001
- value
- 49
- group Id
- BG002
- value
- 130
- group Id
- BG003
- value
- 69
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 16
- group Id
- BG007
- value
- 384
- title
- Between 18 and 64 years
- measurements
- group Id
- BG000
- value
- 28
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 104
- group Id
- BG003
- value
- 47
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 10
- group Id
- BG007
- value
- 212
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 138
- group Id
- BG001
- value
- 65
- group Id
- BG002
- value
- 234
- group Id
- BG003
- value
- 116
- group Id
- BG004
- value
- 8
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 26
- group Id
- BG007
- value
- 596
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 10
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 20
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 123
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 201
- group Id
- BG003
- value
- 101
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 9
- group Id
- BG006
- value
- 21
- group Id
- BG007
- value
- 516
- title
- White
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 46
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- The baseline analysis population was the intent-to-treat population, defined as all randomized participants with participants analyzed according to the study drug assigned via randomization
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle